Study Title

177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer

Study Details

Description:

This phase 1 dose-escalation and dose-expansion study is designed to evaluate the safety and tolerability of olaparib in combination with 177Lutetium-Prostate Specific Membrane Antigen (177 Lu-PSMA) in patients with metastatic castration resistant prostate cancer (mCRPC).

Sponsor:

Peter MacCallum Cancer Centre

Contacts:

Shahneen Sandhu

shahneen.sandhu@petermac.org

+61 3 8559 7902

Michael Hofman

michael.hofman@petermac.org

+61 3 8559 6914

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468